Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

International Institute of Cancer Immunology, Inc.

Boston Biomedical, Inc.

Yosuke Takanashi

Hitoshi Ban

Masashi Goto

Yukihiro Nishio

Chiang Jia Li

Toshio Nishihara

Katsumi Kubota

Futoshi Hasegawa

Toshio Kanai

Masanori Tobe

Shingo Tojo

Katsunori Tsuboi

Manabu Kusagi

Atsushi Suwa

Toshihiko Sone

Tomoaki Nakamura

Tomohiro Kodama

Tomoya Shiro

Natsuko Suginobe

Yusuke Imazaki

Yoshiko Iwata

The present invention relates to a compound useful as a vaccine adjuvant for cancer vaccine, a preparation process thereof, a pharmaceutical composition comprising the compound, and use of the compound as a vaccine adjuvant for cancer vaccine.

Water soluble adjuvant and composition containing same

The present application relates to WT1 helper peptides consisting of an amino acid sequence of 9 to 30 amino acid residues including a sequence: KLSHL as part thereof, and combinations of a WT1 helper peptide and a conjugate of cancer antigen peptides.

WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides

A compound represented by formula (1-1): wherein b represents an integer of 1 to 5; and Z is a group represented by formula (Z-1), formula (Z-2), formula (Z-3), formula (Za-1), formula (Za-2), formula (Za-3), formula (Za-4) or formula (Za-5),or a salt thereof.

Antibody-drug conjugates including hemiasterlin derivative

A compound represented by the formula (1): wherein Xand Yare each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, Ris a hydrogen atom, a group represented by the formula (2): wherein Xand Yare each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.

WT1 antigen peptide conjugate vaccine

The present invention provides a compound represented by the formula (1): wherein Xand Yare each a single bond or the like, cancer antigen peptide A is an MHC class I-restricted cancer antigen peptide, andRis a hydrogen atom; a group represented by the formula (2): wherein Xand Yare each a single bond or the like, and cancer antigen peptide B is different from the cancer antigen peptide A and is an MHC class I or II-restricted cancer antigen peptide; a group represented by the formula (3): wherein Xand Yare each a single bond or the like, and cancer antigen peptide C is an MHC class II-restricted cancer antigen peptide; or cancer antigen peptide D, wherein the cancer antigen peptide D is an MHC class I or II-restricted cancer antigen peptide containing one cysteine residue,or a salt thereof, for example.

Conjugate vaccine using trimming function of ERAP1

The present invention provides a bicyclic heterocyclic amide derivative of formula (1) wherein ring Qis optionally-substituted Caryl group, etc.; Rand Rare independently hydrogen atom, etc.; Wis optionally-substituted Calkylene group; Wis &#x2014;NRC(O)&#x2014;, etc. wherein Ris hydrogen atom or Calkyl group; Cyis the following group of formula (11), etc.; ring Qis optionally-substituted benzene ring, etc.; n and m are independently 0, 1 or 2, provided that n and m are not simultaneously 0; X is NR, etc.; Ris hydrogen atom, etc.; p is 1, 2, 3, 4 or 5; Ris, independently when two or more exist, hydrogen atom, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming ability of cancer cells and are useful as an orally-available anti-tumor agent. 

Bicyclic heterocyclic amide derivative

Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, Ris optionally substituted heteroaryl etc.; Ris hydrogen etc.; Rand Rare each independently hydrogen etc., Ris the following group: (wherein Y is optionally substituted five membered heteroaryl etc., Ris optionally substituted aryl etc., Rand Rare each dependently hydrogen etc., and m is the integral 0 etc.) etc.; Ris hydrogen etc.; and Ris hydrogen etc. 

Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative

The present invention provides: an uracil derivative represented by general formula (I) or a physiologically acceptable salt thereof (in the formula, Rrepresents a hydrogen atom, a Calkyl group, a Calkene group or a 3- to 6-membered saturated or 4- to 6-membered unsaturated aliphatic ring group which may contain 1 to 2 hetero atoms independently selected from the group consisting of N, O and S; Rrepresents a hydrogen atom, a halogen atom, a cyano group, &#x2014;NRR, &#x2014;N&#x2550;CHN(CH), or an Calkyl group; Arand Arindependently represent a 5- to 6-membered aromatic ring group which may contain 1 to 3 hetero atoms independently selected from the group consisting of N, O and S; and L represents a 6-membered aromatic ring group which may contain 1 to 4 nitrogen atoms, a pyrazole group, a triazole group, or an imidazole group); and a therapeutic agent or prophylactic agent for various inflammatory diseases associated with elastase, comprises the compound or the like as an active ingredient. 

Uracil derivative and use thereof for medical purposes

Growing community of inventors

Osaka, Japan

Yosuke Takanashi